The Universitat Autònoma de Barcelona (UAB) is one of the major public universities of Spain. It is located in Bellaterra, close to Barcelona. Currently, the University offers 87 bachelor’s degrees, covering a wide range of fields such as humanities and arts, social sciences, health sciences, technology and physical sciences. Furthermore, the UAB offers 133 Master’s degrees, as well as 8 Erasmus Mundus Master’s degrees; more than 1,114 PhD dissertations have been elaborated within its doctoral programs. The University has over 37,700 students, almost 3,700 researchers and teaching staff, and it hosts more than 6,000 foreign students.
Thus, the UAB is among the leading Spanish universities in world rankings such as the QS World University Rankings (QS WUR), the Times Higher Education World University Rankings (THE WUR) and the Academic Ranking of World Universities (ARWU), and occupies a world leading position among young universities according to specific classifications.
According to the Ranking QS WUR 2018, which classifies the 500 best universities in the world, the UAB is considered as the third university in Spain and is ranked 195th worldwide (and 89th in Europe).
The UAB is the 2nd Spanish university in the ranking THE WUR 2018 and the 2nd Spanish university by volume of publications indexed in SCOPUS according to the ranking of the research activity SIR WR 2014.
The KI is a medical school and research organization. The Department of Laboratory Medicine investigates within the research areas cancer, Alzheimer’s disease, Progeria and others. The core activities of the Department of Laboratory Medicine are research and education, bringing together basic scientific research, clinical research and healthcare. As a result, the Department holds a strategic position with good conditions for translational research, thanks to its strong basic scientific capability, high technical content and access to clinical problems and clinical materials.
ACIB is an international non-profit competence centre specializing on gapping the bridge between academic and industrial research. With approximately 200 of our own employees and expertise from our currently 16 scientific partners ACIB offers a multi-disciplinary team of experts in all fields of industrial biotechnology. The main ACIB locations are in Austria (Vienna, Graz, Tulln, Innsbruck, Linz), but include also international sites in Germany, Poland, Slovenia, Spain and Italy. ACIB has an excellent track record in joint international research projects and is currently involved in several EU-projects (from FP7 and H2020 to JTIs and ERA-Nets).
ANTIBODYBCN is a registered trademark of AbBcn S.L., a SMEs company dealing in the sale of antibodies and other reagents for research in Biomedicine and Biotechnology. It was created by a team of researchers to make it easier for research laboratories to obtain reagents and manage purchases.
Our R & D department is working on projects with the aim of finding interesting biomarkers in order to do diagnosis or therapy of different human diseases or abnormal states. In the present project, our contribution is to train researchers in the production of antibodies against surface biomarkers of target cells.
Vecura is a core facility at the Clinical Research Centre at the Karolinska University Hospital, which has the mission to meet the need of production of GMP level products including advanced therapy medicinal products for clinical trials. Vecura has served as contract manufacturer for more than 10 years and has supplied GMP products for more than 15 clinical trials in different countries in Europe. More than 200 patients have been treated with products produced by Vecura. Vecura is approved by the Swedish Medical Products Agency as a manufacturer of cell- and gene therapy products for clinical trials. The business is licensed as an establishment both from the National Board of Health and manufacturing authorization for investigational medicinal products issued by the Medicinal Products Agency. Vecura belongs to Karolinska University Hospital and funded by the Stockholm County Council and a number of research grants.
ADSI was founded in 2012 as a research enterprise of the Leopold Franzens University of Innsbruck (LFU) and offers contract services for companies as well as academic research institutes in the fields of drug development, phytopharma, dietary supplements, phytocosmetics, nutrition and related industries.
The ADSI was initiated by the analytical chemist Prof. Dr. Günther K. Bonn, Head of the Institute of Analytical Chemistry and Radiochemistry, University of Innsbruck, and by the cell biologist and physician Prof. Dr. Lukas A. Huber, Head of the Cell Biology Division at the Medical University of Innsbruck. Both Prof. Bonn and Prof. Huber are the scientific directors of the ADSI.
The ADSI employs about 25 persons, mainly highly qualified scientists. The institute is equipped with state of the art high-tech infrastructure for analytical chemistry and High-content drug screening. It became an integral part of the Austrian research landscape and works closely with numerous universities and research institutions, as well as with industrial partners in Austria and abroad.
This project is co-funded by the European Union’s Horizon 2020 Research and Innovation Programme under Reference N. H2020-MSCA-RISE-2017 GA778325
Prof. Manuel Valiente
Universitat Autònoma de Barcelona,
Science Faculty. Building
(+34) 93 581 49 38